These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 11872417

  • 1. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N, Qureshi A, Ahmed AR.
    Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
    [Abstract] [Full Text] [Related]

  • 2. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
    Ahmed AR.
    J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
    [Abstract] [Full Text] [Related]

  • 3. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.
    Sami N, Bhol KC, Razzaque Ahmed A.
    Clin Immunol; 2002 Jan; 102(1):59-67. PubMed ID: 11781068
    [Abstract] [Full Text] [Related]

  • 4. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
    Ahmed AR.
    J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
    [Abstract] [Full Text] [Related]

  • 5. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
    Sami N, Qureshi A, Ruocco E, Ahmed AR.
    Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins].
    Szép Z, Danilla T, Buchvald D.
    Cas Lek Cesk; 2005 Sep; 144(10):700-3. PubMed ID: 16279438
    [Abstract] [Full Text] [Related]

  • 7. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
    Engineer L, Bhol KC, Ahmed AR.
    J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
    [Abstract] [Full Text] [Related]

  • 8. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
    Segura S, Iranzo P, Martínez-de Pablo I, Mascaró JM, Alsina M, Herrero J, Herrero C.
    J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
    [Abstract] [Full Text] [Related]

  • 9. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease.
    Chrissafidou A, Malek M, Musch E.
    Z Gastroenterol; 2007 Jul; 45(7):605-8. PubMed ID: 17620224
    [Abstract] [Full Text] [Related]

  • 10. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.
    Werth VP.
    Arch Dermatol; 1996 Dec; 132(12):1435-9. PubMed ID: 8961871
    [Abstract] [Full Text] [Related]

  • 11. The role of IVIg treatment in severe pemphigus vulgaris.
    Baum S, Scope A, Barzilai A, Azizi E, Trau H.
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):548-52. PubMed ID: 16684282
    [Abstract] [Full Text] [Related]

  • 12. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy.
    Ahmed AR, Sami N.
    J Am Acad Dermatol; 2002 Jan; 46(1):42-9. PubMed ID: 11756944
    [Abstract] [Full Text] [Related]

  • 13. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
    Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D.
    Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
    [Abstract] [Full Text] [Related]

  • 14. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM, Ahmed AR.
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [Abstract] [Full Text] [Related]

  • 15. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.
    Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR.
    Clin Immunol; 2004 Jun; 111(3):303-10. PubMed ID: 15183151
    [Abstract] [Full Text] [Related]

  • 16. A single cycle of rituximab for the treatment of severe pemphigus.
    Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P.
    N Engl J Med; 2007 Aug 09; 357(6):545-52. PubMed ID: 17687130
    [Abstract] [Full Text] [Related]

  • 17. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus.
    Saha M, Powell AM, Bhogal B, Black MM, Groves RW.
    Br J Dermatol; 2010 Apr 09; 162(4):790-7. PubMed ID: 19922532
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)].
    Benoit Corven C, Carvalho P, Prost C, Verret JL, Saiag P, Noblesse I, Bedane C, Chosidow O, Young P, Roujeau JC, Joly P.
    Ann Dermatol Venereol; 2003 Jan 09; 130(1 Pt 1):13-5. PubMed ID: 12605150
    [Abstract] [Full Text] [Related]

  • 19. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.
    Keskin DB, Stern JN, Fridkis-Hareli M, Razzaque Ahmed A.
    Cytokine; 2008 Mar 09; 41(3):315-21. PubMed ID: 18289869
    [Abstract] [Full Text] [Related]

  • 20. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.
    Heaphy MR, Albrecht J, Werth VP.
    Arch Dermatol; 2005 Jun 09; 141(6):699-702. PubMed ID: 15967915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.